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Objectives: To assess health care professional’s judgments on economic con-
sequences of prescribed medical interventions and their responsiveness of 
different health care policy measures aiming for increasing their cost-conscious-
ness. MethOds: The design encompassed the nation-wide-cross-sectional hier-
archical levels of health care facilities across the geographical regions. Authors 
used validated and standardized Likert scale of Health Economic Awareness (HEA) 
adjusted for local setting to evaluate health care professionals by face-to-face inter-
views. The questionnaire comprehended clinician’sattitudes on: Clinical-Decision-
Making-Alternative-Interventions (CDMAI); Quality-of –Health-care (QHC); and 
Cost-Containment-Policy (CCP). This survey was conducted in two waves before 
and after policy intervention in 40 hospitals and primary care facilities in fifteen 
cities in Serbia from January 2010-December 2012. A total of 649 participants were 
interviewed before the intervention and 651 after the intervention. Core Republican 
Health Insurance Fund adopted and disseminated the package of cost containment 
measures through the Nation-wide pharmacoeconomic guidelines which princi-
pally targeted at prescribers. Pharmacists, physicians and dentists were examined 
by the scores of CDMAI, QHC, CCP and HEA. Results: Pharmacists and dentists 
had a higher average score (mean±s.d.) of CDMAI by the pharmacists (1.200±0.421) 
and the dentists (1.195±0.560) than the score of physicians (1.017±0.453). Dentists 
had the highest average score of CCP (2.127±0.598) and then the score of physicians 
(1.976±0.529). The score of pharmacists was the lowest (1.854±0.461).There were no 
impacts of the interventions on the professional behaviors regarding the scores 
of QHQ, CDMAI, CCP, and HEA. cOnclusiOns: Health economic awareness has 
differed substantially among of different health care professionals. Health policy 
measures were implemented to reduce non-cost-effective prescribing behaviors 
but the effects are non-clear-cut evidences. This experimental study is a pioneering 
effort in the wider Balkans region.
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Objectives: To assess the efficacy and safety of agomelatine using pharma-
covigilance during 12-week follow-up. MethOds: Agomelatine 25-50 mg was pre-
scribed open label to patients with depressive disorders diagnosed by psychiatrists 
based on DSM-IV/ICD-10 criteria. Treatment options were intent-to-treat. All 480 
patients, including 97 elderly patients were followed up at week 2 if dose titra-
tion was necessary. Efficacy was assessed using Montgomery-Äsberg Depression 
Rating Scale(MÄDRS) and clinical global impression of improvement (CGI-I) and of 
severity (CGI-S) scales, at weeks 2, 6, and 12. Data on adverse effects and for reports 
were gathered through patient interviews. Results: Of 480 patients, 20-86 years 
(mean[SD] 49.6[14.5]), 247(51.5%) were men and 97(20.2%) were elderly (65 to 86; 
mean[SD] 71.1[5.0]). Among all patients, 225(46.9%) and 255(53.1%) were depressed 
with a single episode and recurrent episodes. Patients with recurrent episodes were 
taking various classes of antidepressants, including selective serotonin reuptake 
inhibitors in 328(50.9%) patients. Generalized anxiety disorder was a concurrent 
diagnosis in 95(24.3%) of patients. The respective mean(SD) baseline CGI-S, CGI-I, 
and MADRS scores of 3.90(0.68), 4.15(0.76), and 22.59(3.77) were reduced to 2.1(0.31), 
1.11(0.37), and 9.19(2.03), with respective reductions in mean(SD; 95% CI) scores of 
1.78(0.75;1.72-1.85), 2.98(0.78;2.91-3.05), and 13.39(4.36; 13.00-13.78). Similar efficacy 
was evidenced for elderly depressed patients (N= 97), in whom mean(SD) MADRS 
score at baseline 22.37(4.79) was consistently significantly reduced to 14.61(3.04), 
10.76(3.04), and 8.72(1.91) at weeks 2, 6, and 12, respectively. After 12 weeks, over-
all remission (MADRS score < 10) was seen in 68.4% of patients with moderate to 
severe (MADRS > 25) depression and in 73.4% of elderly depressed patients. The 
mild adverse events reported were dizziness(9.5%), headache(7.4%), difficulty sleep-
ing(6.3%), and nausea(3.1%). There were no cases reported of alanine transaminase 
levels three times above upper limit of normal. cOnclusiOns: Agomelatine has 
proven to be a safe and effective new antidepressant in intent-to-treat analysis of 
depressed, including elderly, patients in daily clinical practice in Thailand.
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Objectives: Second generation antipsychotics (SGA) are associated with increased 
risk of metabolic side effects. A systematic literature review and mixed treatment 
comparisons (MTC) were performed to assess the efficacy and the metabolic side 
effects of antipsychotics, and more especially to compare lurasidone to other widely 
used antipsychotics in patient with acute schizophrenia. MethOds: This review 
included short-term (≤ 12 weeks) randomised controlled trials (RCTs) in patients 
with an acute phase of schizophrenia. The literature search was based on the 
NICE guidelines on treatment for schizophrenia published in 2010. A systematic 
search in the most comprehensive medical databases of peer-reviewed articles 
(MEDLINE, EMBASE, CENTRAL) was conducted until June 2012 to update the evi-
dence. In addition to lurasidone, eight comparators were considered: amisulpride, 
aripiprazole, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone and pla-
cebo. A Bayesian ramdom effect MTC was performed on efficacy outcomes (PANSS 
total score and CGI-S score) and metabolic side effects (weight, triglycerides, total 
cholesterol level and fasting glucose level). Results: Thirty-nine RCTs involving 
12,721 patients were included. Results showed that lurasidone had similar efficacy 
deviation] age 10.7 [2.75] years, 99% Caucasian, 82% male, 76% combined ADHD 
subtype). Variables associated with worsening severity were: baseline parental 
occupation (P= .003), poorer school outcomes (P< .001), and use of psychoeducation 
(P= .004). Initial use of nonstimulants (vs. stimulants) was associated with significant 
improvement on the CHIP-CE total score at 3 months and 9-24 months postbaseline. 
The estimated adjusted difference between treatments was −6.0 (95% confidence 
interval: −7.9, −4.1) at 24 months postbaseline. cOnclusiOns: In this observational 
study, worsening of ADHD symptoms was associated with initial use of psychoe-
ducation, parental occupation, and poorer school outcomes. Initial treatment with 
nonstimulants (vs. stimulants) was associated with improved QoL.
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Objectives: To assess the efficacy of a cognitive enhancer, donepezil, as an adju-
vant treatment to antipsychotics on clinical outcomes of schizophrenia. MethOds: 
Systematic review with meta-analysis to obtain appropriate evidence from rand-
omized clinical trials (RCTs) on the efficacy of donepezil plus antipsychotics versus 
placebo plus antipsychotics in patients diagnosed with schizophrenia for the follow-
ing outcomes: general psychopathology, positive/negative symptoms, and depres-
sive symptoms. Effect size estimates corrected for small sample size trials (Hedges’ 
g) were calculated for parallel trials and cross-over trials. Negative values for Hedges’ 
g denote an effect favouring the combined treatment. When needed, values for the 
cross-over correlation were imputed from available individual data to obtain the 
Hedges’ g estimates. The individual estimates were pooled with a random-effects 
meta-analysis. Results: Seven trials (4 cross-over, 3 parallel) were included. Four 
trials provided data on the Positive and Negative Syndrome Scale (PANSS) for total 
and general psychopathology scores. Three trials provided data for PANSS positive 
scores and 5 trials provided data for PANSS negative scores. Three trials provided 
data on depression scores. The combined treatment did not show differences in 
any of the assessed outcomes: PANSS total scores (g = -0.57, 95% CI = -2.11 to 0.96, 
I2 = 67%); PANSS General Psychopathology scores (g = -0.20, 95% CI = -0.74 to 0.34, 
I2 = 0%); PANSS positive symptoms (g = -0.06, 95% CI = -0.73 to 0.60, I2 = 0%); PANSS 
negative symptoms (g = -0.43, 95% CI = -1.98 to 1.12, I2 = 86%); depression scores (g = 
-0.35, 95% CI = -1.20 to 0.49, I2 = 0%). cOnclusiOns: The combination of donepezil 
with antipsychotic treatment does not improve clinical outcomes in schizophrenia.
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Objectives: Levomilnacipran (1S,2R-milnacipran) is a potent and selective seroto-
nin and norepinephrine reuptake inhibitor (SNRI) with approximately 2-fold greater 
potency for reuptake inhibition of norepinephrine than serotonin. Levomilnacipran 
SR is in late-stage clinical development for the treatment of major depressive dis-
order (MDD) in adults. A pooled analysis of Phase III studies was conducted to 
evaluate the effects of levomilnacipran SR treatment on functional health and 
well-being. MethOds: Pooled analysis of three double-blind, placebo-controlled, 
Phase III randomized clinical trials (Clinicaltrials.gov #NCT00969709, NCT00969150, 
NCT01034462), which included one fixed-dose (levomilnacipran SR 40, 80 or 120 mg/
day or placebo) and two flexible-dose (levomilnacipran SR 40-120 mg/day or placebo) 
studies that included the acute version of the SF-36v2 health survey. Percentage of 
responders following 8-weeks of treatment (observed cases) with levomilnacipran 
SR or placebo were compared for each individual health domain and the Physical 
(PCS) and Mental (MCS) Component Summary scores based on individual patient-
level responder criteria for minimally important differences. Estimates of odds 
ratios, 95% confidence intervals and p-values were from a logistic regression model 
with study and treatment as factors, baseline score as covariate and a study-by-
treatment interaction term. Results: Compared with placebo-treated patients, 
a greater percentage of patients who were treated with levomilnacipran SR were 
considered as responders. Homogeneity of OR could be assumed for the individual 
health domains and component summary scores except for the Bodily Pain scale 
(study-by-treatment interaction p-value= 0.0123). Pooled OR [95%-CI] for being a 
responder were as follows: MCS= 1.705 [1.292-2.250]; PCS= 1.285 [0.972-1.700]; General 
Health= 2.324 [1.763-3.064]; Social Functioning= 1.698 [1.295-2.226]; Vitality= 1.608 
[1.250-2.068]; Mental Health= 1.579 [1.203-2.072]; Role-Emotional= 1.453 [1.121-1.882]; 
Physical Functioning= 1.382 [1.032-1.850]; and Role-Physical= 1.341 [1.005-1.788]. All 
OR (except PCS) were statistically significant (p< 0.05). cOnclusiOns: Compared 
with placebo, patients who are treated with levomilnacipran SR are more likely to 
achieve meaningful improvement in multiple domains of health as measured by 
the SF-36 Health Survey.
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